Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Greehey Children's Cancer Research Institute to expand its drug candidates, LP-184 and LP-284, into rare pediatric cancers. This partnership aims to validate findings from the RADR® platform and advance treatments for difficult-to-treat tumors like rhabdomyosarcoma and ATRT. The collaboration leverages GCCRI's expertise and models, seeking to accelerate pediatric cancer therapy development at reduced costs. Lantern has previously received FDA orphan drug designations for LP-184.
Lantern Pharma (LTRN) announced that the FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation for its drug candidate LP-184, aimed at treating pediatric patients with ATRT (Atypical Teratoid Rhabdoid Tumor). LP-184 is also being investigated for genetically defined solid tumors like pancreatic cancer and GBM. The Rare Pediatric Disease designation may allow Lantern to receive a priority review voucher for future product applications. The firm focuses on using its RADR® A.I. platform to identify effective treatments tailored to patient genetics.
Lantern Pharma (NASDAQ: LTRN) announced a collaboration with The Danish Cancer Society Research Center to advance clinical development of its drug candidates, LP-100 and LP-184. This partnership aims to enhance diagnostic methods for identifying NER-deficient tumors. The collaboration will leverage Lantern's RADR® AI platform, potentially adding millions of data points and expediting cancer treatment discovery. Both LP-100 and LP-184 have shown promise in targeting NER deficiencies, with LP-100 currently in a phase 2 trial for metastatic prostate cancer, showing improved overall survival rates.
Lantern Pharma (LTRN) has expanded its collaboration with the National Cancer Institute (NCI) to enhance the development of its oncology drug candidates, LP-184 and LP-284. This partnership aims to leverage multiomic data to identify gene signatures predicting tumor responses. LP-184 is targeting pancreatic cancer and glioblastoma, while LP-284 focuses on leukemias and lymphomas. Initial results suggest LP-184 may be more effective in tumors resistant to current treatments. The partnership will continue to refine predictive biomarkers and advance clinical trials, with results expected to be published in peer-reviewed journals.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its CEO Panna Sharma will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be a fireside chat with analyst Michael King and will be available on-demand for attendees starting January 10 at 7:00 AM ET. Lantern Pharma utilizes its RADR® A.I. platform for oncology drug development, focusing on biomarker identification to enhance treatment outcomes for patients. More information can be found on their website.
On December 14, 2021, Lantern Pharma (NASDAQ: LTRN) announced positive data on LP-284's efficacy against hematologic cancers presented at the ASH Annual Meeting. LP-284, a synthetic acylfulvene compound, showcased broad anti-tumor activity against lymphoma, multiple myeloma, and leukemia in vitro. The findings suggest LP-284 could serve as a targeted therapy option for cancers with DNA repair deficiencies. Lantern plans to leverage its RADR® A.I. platform to advance LP-284 development and address the urgent need for new treatment options in blood cancers.
Lantern Pharma Inc. (NASDAQ: LTRN) has announced a share repurchase program to buy back up to $7 million of its common stock. This initiative aligns with the company's goal to enhance shareholder value and reflects confidence in its clinical pipeline and RADR® A.I. platform. As of September 30, 2021, Lantern held approximately $73.8 million in cash and marketable securities, with around 11.2 million shares outstanding as of October 29, 2021. The stock buyback will be executed based on market conditions and regulatory limitations.
Lantern Pharma (NASDAQ: LTRN) announced a virtual Key Opinion Leader (KOL) event on pancreatic cancer treatment featuring drug candidate LP-184. Scheduled for November 18, 2021, at 12:00 pm EST, the event will discuss LP-184's advances, a PTGR1-activated small molecule targeting genetically defined pancreatic cancer patients. Notable co-hosts include Dr. Igor Astsaturov, Dr. Ira Sharp, and Dr. Kishor G. Bhatia. Lantern's RADR® A.I. platform aims to transform oncology drug development. LP-184 has Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma.
Lantern Pharma (LTRN) announced its abstract on the efficacy of LP-184 in treating glioblastoma multiforme (GBM) has been accepted for virtual presentation at the Society for Neuro-Oncology 2021 Annual Meeting from November 18-21, 2021. The research indicates LP-184's effectiveness in both MGMT methylated and unmethylated GBM, particularly for those with DNA repair deficiencies. LP-184 has also received Orphan Drug Designation for malignant gliomas and pancreatic cancer. The findings support further development as a promising treatment for GBM.
On November 9, 2021, Lantern Pharma (NASDAQ: LTRN) announced its participation in two investor conferences. CEO Panna Sharma will present at the Q4 Investor Summit on November 16 at 11:00 am ET, available via webcast. CFO David Margrave will hold one-on-one meetings at the Torrey Hills Capital 6th Annual Emerging Growth Conference on November 17 in Rancho Santa Fe, California. Lantern Pharma focuses on oncology drug development using its RADR® A.I. platform, which identifies patients likely to respond to targeted therapeutics.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
